ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 218 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202 | -18.9% | 37,100 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $249 | -24.1% | 37,100 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $328 | +15.9% | 37,100 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $283 | -99.8% | 37,100 | +71.8% | 0.00% | +100.0% |
| Q3 2022 | $154,000 | -12.0% | 21,600 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $175,000 | -41.7% | 21,600 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $300,000 | -50.5% | 21,600 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $606,000 | -17.4% | 21,600 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $734,000 | -16.9% | 21,600 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $883,000 | +2.9% | 21,600 | +1.4% | 0.01% | 0.0% |
| Q1 2021 | $858,000 | -16.6% | 21,300 | +22.4% | 0.01% | -16.7% |
| Q4 2020 | $1,029,000 | +21.6% | 17,400 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $846,000 | -55.4% | 17,400 | -55.6% | 0.01% | -25.0% |
| Q2 2020 | $1,896,000 | – | 39,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |